Benign Prostatic Hyperplasia and Lower Urinary Tract Symptoms in African Americans and Latinos: Treatment in the Context of Common Comorbidities

Colón, Iván; Payne, Richard E.

doi:10.1016/j.amjmed.2008.05.023

Cited by 8 publications

(3 citation statements)

References 56 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Patients who were diagnosed with benign prostatic hyperplasia with lower urinary tract symptoms, also frequently had associated hypertension and cardiovascular disease. Colon &Payne in 2008 andParsons et al in 2006 reported that patients with metabolic disorder like diabetes, hyperlipidaemia are prone for benign prostatic hyperplasia [16,17]. Hence it was postulated that, metabolic disorder and benign prostatic hyperplasia have underlying dysfunction in insulin uptake of glucose and resulting in hyperinsulinaemia.…”

Section: Discussionmentioning

confidence: 99%

A Study of Effectiveness of Medical Therapy in Benign Prostatic Hyperplasia Patients in HUSM

Hamzah¹,

Hood²,

Adnan³

et al. 2015

J. Infect. Dis. Ther.

View full text Add to dashboard Cite

Introduction: Benign prostate hyperplasia (BPH), a progressive disease, can cause various urinary complications if left untreated. Aims and Objective: The current study was desigined to compare international prostate symptom score (IPSS), urine flow rate (Qmax), Prostate specific antigen (PSA) in pre and post treatment among patients with Benign prostate hyperplasia and to asses their quality of life. Methodology: A cross sectional study was designed at Hospital Universiti Sains Malaysia, including all patients diagnosed as BPH from year 2007 to 2010. Based on inclusion and exclusion criteria 307 subjects were selected. New set of International Prostate Symptom Score (IPSS) and urine flow rate (Qmax) was obtained from all selected patients. SPSS version 19 was used for statistical analysis. Result: Out of the 307 patients currently treated at Hospital University Sains Malaysia (HUSM), 268(87.3%) were Malays, 38(12.4%) were Chinese and 1(0.3%) was Indian. Majority of the patients having BPH were above 50 years of age. One hundred and seven (34.9%) patients were associated with hypertension, followed by diabetes mellitus 12 (3.9%). urine peak flow rate (Qmax) had mean difference of 11.74 and 14.41ml/ sec, which shows the medical therapy do improve urine flow rate and benign prostatic hyperplasia (p<0.001). The prostate size also showed an increase having mean difference from 36.12 to 38.14cc 3 (p<0.001). There is significant relation between prostate gland volume and serum prostatic specific antigen (p<0.001). Conclusion: Benign prostatic hyperplasia although a benign condition, but still interferes with the normal life style of the patients. By initiating medical treatment this disease can not only be treated but also significantly improves the quality of life of the patients.

show abstract

Section: Discussionmentioning

confidence: 99%

A Study of Effectiveness of Medical Therapy in Benign Prostatic Hyperplasia Patients in HUSM

Hamzah¹,

Hood²,

Adnan³

et al. 2015

J. Infect. Dis. Ther.

View full text Add to dashboard Cite

show abstract

“…Heritability of LUTS scores in twins has been estimated at 20–40% 22 , with some estimates as high as 83% 23 , while heritability of benign prostate disease has been estimated at 49% from twin studies 24 . The presence of racial disparities also supports a genetic contribution to BPH risk 25,26 . Evaluation of the SNP-based additive genetic heritability has not yet been published.…”

Section: Introductionmentioning

confidence: 78%

Heritability and genome-wide association study of benign prostatic hyperplasia (BPH) in the eMERGE network

Hellwege

Stallings²,

Torstenson

et al. 2019

Sci Rep

View full text Add to dashboard Cite

Benign prostatic hyperplasia (BPH) results in a significant public health burden due to the morbidity caused by the disease and many of the available remedies. As much as 70% of men over 70 will develop BPH. Few studies have been conducted to discover the genetic determinants of BPH risk. Understanding the biological basis for this condition may provide necessary insight for development of novel pharmaceutical therapies or risk prediction. We have evaluated SNP-based heritability of BPH in two cohorts and conducted a genome-wide association study (GWAS) of BPH risk using 2,656 cases and 7,763 controls identified from the Electronic Medical Records and Genomics (eMERGE) network. SNP-based heritability estimates suggest that roughly 60% of the phenotypic variation in BPH is accounted for by genetic factors. We used logistic regression to model BPH risk as a function of principal components of ancestry, age, and imputed genotype data, with meta-analysis performed using METAL. The top result was on chromosome 22 in SYN3 at rs2710383 (p-value = 4.6 × 10 −7 ; Odds Ratio = 0.69, 95% confidence interval = 0.55–0.83). Other suggestive signals were near genes GLGC , UNCA13 , SORCS1 and between BTBD3 and SPTLC3 . We also evaluated genetically-predicted gene expression in prostate tissue. The most significant result was with increasing predicted expression of ETV4 (chr17; p-value = 0.0015). Overexpression of this gene has been associated with poor prognosis in prostate cancer. In conclusion, although there were no genome-wide significant variants identified for BPH susceptibility, we present evidence supporting the heritability of this phenotype, have identified suggestive signals, and evaluated the association between BPH and genetically-predicted gene expression in prostate.

show abstract

“…The incidence of BPH in Asians and Caucasians is similar, but the incidence of prostate cancer (PCa) in Asians is lower than in Caucasians [1]. A high incidence of BPH was also reported in African Americans and Latinos, too [2–4]. As the life span increases in most countries, BPH may become a more common and problematic disease for males in their late middle age and beyond.…”

Section: Part I: Benign Prostatic Hyperplasiamentioning

confidence: 99%

Androgen receptor and immune inflammation in benign prostatic hyperplasia and prostate cancer

Izumi

Chang

2014

Clinical Investigation

View full text Add to dashboard Cite

Both benign prostatic hyperplasia (BPH) and prostate cancer (PCa) are frequent diseases in middle-aged to elderly men worldwide. While both diseases are linked to abnormal growth of the prostate, the epidemiological and pathological features of these two prostate diseases are different. BPH nodules typically arise from the transitional zone, and, in contrast, PCa arises from the peripheral zone. Androgen deprivation therapy alone may not be sufficient to cure these two prostatic diseases due to its undesirable side effects. The alteration of androgen receptor-mediated inflammatory signals from infiltrating immune cells and prostate stromal/epithelial cells may play key roles in those unwanted events. Herein, this review will focus on the roles of androgen/androgen receptor signals in the inflammation-induced progression of BPH and PCa.

show abstract

Benign Prostatic Hyperplasia and Lower Urinary Tract Symptoms in African Americans and Latinos: Treatment in the Context of Common Comorbidities

Cited by 8 publications

References 56 publications

A Study of Effectiveness of Medical Therapy in Benign Prostatic Hyperplasia Patients in HUSM

A Study of Effectiveness of Medical Therapy in Benign Prostatic Hyperplasia Patients in HUSM

Heritability and genome-wide association study of benign prostatic hyperplasia (BPH) in the eMERGE network

Androgen receptor and immune inflammation in benign prostatic hyperplasia and prostate cancer

Contact Info

Product

Resources

About